Insider Selling: Hims & Hers Health, Inc. (NYSE:HIMS) Insider Sells $251,984.88 in Stock

Hims & Hers Health, Inc. (NYSE:HIMS) insider Soleil Boughton sold 4,152 shares of the company’s stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $60.69, for a total value of $251,984.88. Following the transaction, the insider now directly owns 157,345 shares in the company, valued at $9,549,268.05. The trade was a 2.57 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Soleil Boughton also recently made the following trade(s):

• On Monday, February 3rd, Soleil Boughton sold 4,153 shares of Hims & Hers Health stock. The shares were sold at an average price of $35.30, for a total transaction of $146,600.90.
• On Tuesday, January 21st, Soleil Boughton sold 54,153 shares of Hims & Hers Health stock. The shares were sold at an average price of $29.90, for a total transaction of $1,619,174.70.
• On Monday, January 6th, Soleil Boughton sold 268,932 shares of Hims & Hers Health stock. The stock was sold at an average price of $27.75, for a total transaction of $7,462,863.00.
• On Tuesday, November 26th, Soleil Boughton sold 2,343 shares of Hims & Hers Health stock. The shares were sold at an average price of $29.90, for a total transaction of $70,055.70.

Hims & Hers Health Trading Down 26.1 %

Shares of NYSE HIMS opened at $49.10 on Friday. The stock has a fifty day simple moving average of $35.05 and a two-hundred day simple moving average of $25.76. Hims & Hers Health, Inc. has a 1-year low of $9.25 and a 1-year high of $72.98. The firm has a market cap of $10.73 billion, a price-to-earnings ratio of 111.58 and a beta of 1.35.

Wall Street Analyst Weigh In

Several analysts have recently commented on HIMS shares. TD Cowen reissued a “buy” rating and issued a $28.00 price objective on shares of Hims & Hers Health in a research note on Wednesday, November 20th. Citigroup cut Hims & Hers Health from a “neutral” rating to a “sell” rating and raised their price objective for the company from $24.00 to $25.00 in a research note on Friday, January 10th. Needham & Company LLC upped their target price on shares of Hims & Hers Health from $28.00 to $31.00 and gave the stock a “buy” rating in a research note on Monday, January 6th. Canaccord Genuity Group increased their target price on shares of Hims & Hers Health from $38.00 to $68.00 and gave the company a “buy” rating in a report on Wednesday. Finally, Morgan Stanley cut shares of Hims & Hers Health from an “overweight” rating to an “equal weight” rating and boosted their price target for the stock from $42.00 to $60.00 in a report on Tuesday, February 18th. Two investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average target price of $28.53.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in HIMS. Crewe Advisors LLC bought a new stake in Hims & Hers Health in the 4th quarter valued at about $28,000. Raleigh Capital Management Inc. increased its stake in shares of Hims & Hers Health by 1,100.0% in the fourth quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company’s stock worth $29,000 after purchasing an additional 1,100 shares in the last quarter. Blume Capital Management Inc. raised its position in shares of Hims & Hers Health by 100.0% in the fourth quarter. Blume Capital Management Inc. now owns 1,200 shares of the company’s stock valued at $29,000 after purchasing an additional 600 shares during the period. Smartleaf Asset Management LLC lifted its stake in shares of Hims & Hers Health by 4,415.6% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the company’s stock valued at $36,000 after buying an additional 1,413 shares in the last quarter. Finally, Summit Securities Group LLC bought a new position in Hims & Hers Health in the 4th quarter worth approximately $38,000. Institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.